Insmed INSM Brensocatib external R&D expenses — R&D

Other product segments

Similar metrics at other companies

IDYADarovasertib — External Clinical Development Expenses

$23.33M+1.4%

NRIXBexobrutideg (NX-5948) — R&D

$28.19M+51.9%

GERNResearch and clinical expenses — R&D

$13M-5.1%

ACRSDrug Candidate Bosakitug — Research And Development Project Spend

$3.14M-7.2%

BCRXBerotralstat — Research and Development Expense (Excluding Acquired in Process Cost)

$1.8M-4.2%

DNLITherapeutics Segment — Research and Development Expense

$103.85M-10.7%

Questions, answered.

What is Insmed's brensocatib external R&D expenses — R&D?

Insmed (INSM) reported brensocatib external R&D expenses — R&D of $18.48M in Q1 2026.

How has Insmed's brensocatib external R&D expenses — R&D changed year-over-year?

Insmed's brensocatib external R&D expenses — R&D decreased by 10.5% year-over-year, from $20.66M to $18.48M.

What is the long-term trend for Insmed's brensocatib external R&D expenses — R&D?

Over 3 years (2022 to 2025), Insmed's brensocatib external R&D expenses — R&D has grown at a -2.0% compound annual growth rate (CAGR), from $102.53M to $96.52M.

What does brensocatib external R&D expenses — R&D mean?

This metric represents the direct external costs incurred for the clinical development and research activities specifically associated with the Brensocatib program. It captures payments to third-party contract research organizations, clinical trial sites, and manufacturing partners dedicated to advancing this specific pipeline asset. Monitoring these expenses provides insight into the capital intensity and progress of the company's key late-stage clinical development efforts.